Retatrutide, a novel dual-acting glucose-dependent incretin agent, represents a significant advance in peptide medicines for the handling of type 2 sugar disorders and, increasingly, obesity. Unlike many existing treatment interventions, retatrutide combines the actions of a GLP-1 receptor stimulant and a GIP receptor stimulant, offering a more hol